Emerging diabetes therapies and technologies

Diabetes Research and Clinical Practice

Volumn 97, Issue 1, 2012, Pages 16-26

  Moser, Emily G ^a,b   Morris, Audrey A ^b   Garg, Satish K ^b,c,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c NONE

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Closed loop devices; Continuous glucose monitors; Insulin; Insulin pens; Insulin pumps; Oral antidiabetic medications; Type 1 and type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DEGLUDEC; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LY 2605541; METFORMIN; NSULIN DEGLUDEC; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIDIABETIC ACTIVITY; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CLOSED LOOP SYSTEM; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PEN; INSULIN PUMP; INSULIN RESISTANCE; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WEIGHT GAIN;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84864092735     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.01.027     Document Type: Review

References (78)

1. Whiting D.R., Guariguanta L., Weil C. Shaw JEIDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Ratner R.E., Research D.P.P. An update on the Diabetes Prevention Program. Endocr Pract 2006, 12(Suppl. 1):20-24.
3. Garg S.K., Ritchie P.J., Moser E.G., Snell-Bergeon J.K., Freson B.J., Hazenfield R.M. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab 2011, 13:137-143.
4. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
6. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group.
7. Hirsch I.B. Insulin delivery devices-pumps and pens. Diabetes Technol Ther 2010, 12(Suppl. 1):S115-S116.
8. Sheldon B., Russell-Jones D., Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab 2009, 11:5-19.
9. Pickup J.C., Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008, 31(Suppl. 2):S140-S145.
10. Owens D.R., Bolli G.B. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 2008, 10:333-349.
11. Vaughn D.E., Yocum R.C., Muchmore D.B., Sugarman B.J., Vick A.M., Bilinsky I.P., et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009, 11:345-352.
12. Zinman B., Fulcher G., Rao P.V., Thomas N., Endahl L.A., Johansen T., et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011, 377:924-931.
13. Simon A.C., Devries J.H. The future of basal insulin supplementation. Diabetes Technol Ther 2011.
14. Steiner S., Hompesch M., Pohl R., Simms P., Flacke F., Mohr T., et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008, 51:1602-1606.
15. Lebovitz H.E., Feinglos M.N. Mechanism of action of the second-generation sulfonylurea glipizide. Am J Med 1983, 75:46-54.
16. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care 1992, 15:737-754.
17. Scott R., Wu M., Sanchez M., Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.
18. Wright A., Burden A.C., Paisey R.B., Cull C.A., Holman R.R., Group UKPD.S. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
19. Haupt E., Knick B., Koschinsky T., Liebermeister H., Schneider J., Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 1991, 17:224-231.
20. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
21. Melin B., Cherqui G., Blivet M.J., Caron M., Lascols O., Capeau J., et al. Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance. Metabolism 1990, 39:1089-1095.
22. Kozka I.J., Holman G.D. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993, 42:1159-1165.
23. Groop L., Widén E., Franssila-Kallunki A., Ekstrand A., Saloranta C., Schalin C., et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989, 32:599-605.
24. Riccio A., Del Prato S., Vigili de Kreutzenberg S., Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabetes Metab 1991, 17:180-184.
25. Perriello G., Misericordia P., Volpi E., Santucci A., Santucci C., Ferrannini E., et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994, 43:920-928.
26. Migoya E.M., Bergeron R., Miller J.L., Snyder R.N., Tanen M., Hilliard D., et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010, 88:801-808.
27. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002, 298:779-784.
28. Cuthbertson J., Patterson S., O'Harte F.P., Bell P.M. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Metabolism 2011, 60:52-56.
29. Bailey C.J. Biguanides and NIDDM. Diabetes Care 1992, 15:755-772.
30. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88.
31. U.K.Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995, 44:1249-1258.
32. Clarke B.F., Campbell I.W. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977, 2:1576-1578.
33. Bailey C.J., Nattrass M. Treatment-metformin. Bailliere Clin Endocrinol Metab 1988, 2:455-476.
34. Herman G.A., Stein P.P., Thornberry N.A., Wagner J.A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther 2007, 81:761-767.
35. Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637. Sitagliptin Study 021 Group.
36. Goldstein B.J., Feinglos M.N., Lunceford J.K., Johnson J., Williams-Herman D.E., Group S.S. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
37. Gallwitz B., Böhmer M., Segiet T., Mölle A., Milek K., Becker B., et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011, 34:604-606.
38. Buse J.B., Sesti G., Schmidt W.E., Montanya E., Chang C.T., Xu Y., et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010, 33:1300-1303.
39. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J.F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
40. Stewart K.M., Wilson M.F., Rider J.M. Insulin delivery devices. J Pharm Pract 2004, 20-28.
41. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008, 6:54-67.
42. Kroon L. An analysis of patient acceptance and safety of a prefilled insulin injection device. J Diabetes Sci Technol 2009, 3:1439-1441.
43. Luijf Y.M., DeVries J.H. Dosing accuracy of insulin pens versus conventional syringes and vials. Diabetes Technol Ther 2010, 12(Suppl. 1):S73-S77.
44. Pearson T.L. Practical aspects of insulin pen devices. J Diabetes Sci Technol 2010, 4:522-531.
45. Davis S., Wei W., Garg S. Clinical impact of initiating insulin glargine with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting. Endocr Pract 2011, 1-27.
46. Jeandidier N., Boivin S. Current status and future prospects of parenteral insulin regimens, strategies and delivery systems for diabetes treatment. Adv Drug Deliv Rev 1999, 35:179-198.
47. Kroon L. Overview of insulin delivery pen devices. J Am Pharm Assoc (2003) 2009, 49:e118-e131.
48. Skyler J.S. Continuous subcutaneous insulin infusion-an historical perspective. Diabetes Technol Ther 2010, 12(Suppl. 1):S5-S9.
49. Meneghini L., Sparrow-Bodenmiller J. Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections. Diabetes Technol Ther 2010, 12(Suppl. 1):S109-S114.
50. Nicolucci A., Maione A., Franciosi M., Amoretti R., Busetto E., Capani F., et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabetes Med 2008, 25:213-220. EQuality1 Study Group-Evaluation of QUALITY of Life and Costs in Diabetes Type 1.
51. Pańkowska E., Błazik M., Dziechciarz P., Szypowska A., Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009, 10:52-58.
52. Franciosi M., Maione A., Pomili B., Amoretti R., Busetto E., Capani F., et al. Correlates of quality of life in adults with type 1 diabetes treated with continuous subcutaneous insulin injection. Nutr Metab Cardiovasc Dis 2010, 20:7-14.
53. Shetty G., Wolpert H. Insulin pump use in adults with type 1 diabetes-practical issues. Diabetes Technol Ther 2010, 12(Suppl. 1):S11-S16.
54. Burdick J., Chase H.P., Slover R.H., Knievel K., Scrimgeour L., Maniatis A.K., et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004, 113:e221-e224.
55. Scaramuzza A.E., Zuccotti G.V. Commentary on 'Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus' with a response from the review authors. Evidence-Based Child Health: A Cochrane Rev J 2010, 5:1870-1872.
56. Maahs D.M., Horton L.A., Chase H.P. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010, 12(Suppl. 1):S59-S65.
57. Anhalt H., Bohannon N.J. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010, 12(Suppl. 1):S51-S58.
58. Garg S., Hirsch I.B. Self-monitoring of blood glucose. Int J Clin Pract 2010, Suppl.:1-10.
59. Kirk J.K., Stegner J. Self-monitoring of blood glucose: practical aspects. J Diabetes Sci Technol 2010, 4:435-439.
60. Ziegler R., Heidtmann B., Hilgard D., Hofer S., Rosenbauer J., Holl R. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes 2011, 12:11-17. DPV-Wiss-Initiative.
61. Freckmann G., Baumstark A., Jendrike N., Zschornack E., Kocher S., Tshiananga J., et al. System accuracy evaluation of 27 blood glucose monitoring systems according to DIN EN ISO 15197. Diabetes Technol Ther 2010, 12:221-231.
62. Hirsch I.B., Verderese C.A. Interference of home blood glucose measurements and poor outcomes: a solvable problem requiring broader exposure. Diabetes Technol Ther 2010, 12:245-247.
63. Garg S. Role of continuous glucose monitoring in Patients with Diabetes Using Multiple Daily Insulin Injections. Infusystems International 2009, 8:17-21.
64. Ellis S.L., Bookout T., Garg S.K., Izuora K.E. Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am 2007, 36(Suppl. 2):46-68.
65. Fabiato K., Buse J., Duclos M., Largay J., Izlar C., O'Connell T. Clinical experience with continuous glucose monitoring in adults. Diabetes Technol Ther 2009, 11:93-103.
66. FreeStyle Navigator Continuous Glucose Monitoring System Users Guide; 2008.
67. Garg S.K., Smith J., Beatson C., Lopez-Baca B., Voelmle M., Gottlieb P.A. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther 2009, 11:65-72.
68. Garg S.K., Hoff H.K., Chase H.P. The role of continuous glucose sensors in diabetes care. Endocrinol Metab Clin North Am 2004, 33:163-173. x-xi.
69. Gilliam L.K., Hirsch I.B. Practical aspects of real-time continuous glucose monitoring. Diabetes Technol Ther 2009, 11(Suppl. 1):S75-S82.
70. Garg S.K., Schwartz S., Edelman S.V. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 2004, 27:734-738.
71. Garg S., Zisser H., Schwartz S., Bailey T., Kaplan R., Ellis S., et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006, 29:44-50.
72. Garg S.K., Potts R.O., Ackerman N.R., Fermi S.J., Tamada J.A., Chase H.P. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999, 22:1708-1714.
73. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2006, 23:1-12.
74. Renard E., Place J., Cantwell M., Chevassus H., Palerm C.C. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care 2010, 33:121-127.
75. Weinzimer S.A., Steil G.M., Swan K.L., Dziura J., Kurtz N., Tamborlane W.V. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008, 31:934-939.
76. El-Khatib F.H., Russell S.J., Nathan D.M., Sutherlin R.G., Damiano E.R. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010, 2:27ra.
77. Castle J.R., Engle J.M., El Youssef J., Massoud R.G., Yuen K.C., Kagan R., et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010, 33:1282-1287.
78. Garg S.K. Impact of insulin delivery devices in diabetes care. Diabetes Technol Ther 2010, 12(Suppl. 1):S1-S3.